News

Click here to answer this week's poll.

Researchers found that apremilast could reduce alcohol intake by more than half per day, on average.

ICYMI, this week we had stories about hidradenitis suppurativa coverage at Winter Clinical Miami, an NDA submission for roflumilast foam, an overview of the 2023 Biosimilars Report from Cardinal Health, and more.

In this week’s Pointers with Dr Portela, the 208SkinDoc shows how to find an ideal and affordable acne skin care routine.

Study participants saw a rapid decrease in inflammatory lesions with the once-daily antibiotic, antibacterial, and retinoid gel.

This week's edition of the Mainstream Patient features stories about treating dry eyelids, face masks for acne-prone skin, acne scar treatments, and more.

A lawsuit, filed by 28 plaintiffs in California, seeks a collective $75,000 in damages.

Researchers link proximity to heavy traffic and risk of atopic dermatitis in new study.

Look back at 10 of the innovative sessions presented at the 2023 Winter Clinical Hawaii Conference in Kohala Coast, Hawaii.

Patients suffering from atopic dermatitis may suffer more during the cold, dry winter month. Bernard Cohen, MD, professor of pediatrics and dermatology at Johns Hopkins University School of Medicine in Baltimore, Maryland, explores various treatment options that will add moisture back into the skin during seasonal flare-ups.

The drug used to treat several dermatological disorders has immunosuppressive effects and has been linked with photosensitizing properties.

Biosimilars have been a trending topic in 2023 with 8 adalimumab biosimilars expected to hit the market this year.

Will Kirby, DO, FAOCD, talks with Blossom Hashemi, MSN, BS, FNP-C, about the best aesthetic career advice, available resources, and the role of allied health care professionals in aesthetics.

Clinicians should strive to address the unique medical and aesthetic challenges seen in vitiligo.

Adolescents and adults with seborrheic dermatitis may have a new topical treatment soon.

Recent research highlighted the important role of the skin’s microbiota in maintaining the homeostasis of the skin and the potential role the human microbiota may play in the development of skin cancer.

It’s crucial for patients and health care providers to consider their personal wellbeing in their daily lives.

Research published in JAMA Dermatology finds dupilumab works quickly and safely for patients with erythrodermic atopic dermatitis.

From topical antibiotics like clindamycin to biologic injectables like adalimumab to surgical options like deroofing, treatment for HS can come in many forms.

Emmy Graber, MD, MBA, covered it all in her Winter Clinical Miami talk, offering take-home pearls via patient case studies.

With now more than 6 months of real-world use for baricitinib available, what challenges still remain for the alopecia areata treatment and what other agents are on the horizon?

Treatment is not mandatory and, in fact, clinicians are still without an FDA-approved treatment option, but parents often insist on some sort of action.

Topicals, orals, biologics—Armstrong’s Winter Clinical Miami presentation focused on new treatment options for patients with psoriasis with an emphasis on real-world observations.

Alexandra Golant, MD, and Seemal Desai, MD, weigh the pros and cons of each treatment option for atopic dermatitis, considering mechanism of action, efficacy, and safety. Which will emerge victorious?

“So much new in the world of pediatric dermatology—new and novel treatments for atopic dermatitis, hemangiomas, childhood blistering diseases, warts. We are practicing during the Golden Age of dermatology,” Swanson says.

The proportion of patients who achieved a SALT score < 10 jumped from 24.9% at 36 weeks to 28.9% at 52 weeks in the BARI 4-mg arm and 11.8% to 15.3% in the BARI 2-mg arm.

When evaluating treatment options for patients with psoriasis, rosacea, or eczema, clinicians should employ a top-down approach and remember to consider topical therapies.

Five days of treatment with the topical therapy measurably improved symptoms and emotional/functional impact for patients with actinic keratosis at week 8.

“We're going to talk about medical hair loss in terms of diagnosis and treatment and really try to make it very easy,” Leavitt says.

From deucravacitinib to roflumilast to tralokinumab and everything in between, James Del Rosso, DO, previews his upcoming Winter Clinical Miami session on new therapies.